Biofrontera Inc. Increase (Decrease) in Accounts Payable and Other Operating Liabilities
Biofrontera Inc. (BFRI) reported Increase (Decrease) in Accounts Payable and Other Operating Liabilities of -$3.32 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities · last filed 2024-11-14
- Biofrontera Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2024-09-30 was $1.01M, a 63.29% decline year-over-year.
- Biofrontera Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2024-06-30 was -$2.08M, a 149.86% decline year-over-year.
- Biofrontera Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2024-03-31 was -$2.25M.
- Biofrontera Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2023-12-31 was $278.00K.
- Biofrontera Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2023 was $6.42M, a 603.40% increase from fiscal 2022.
- Biofrontera Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2022 was $912.00K.
- Biofrontera Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2020 was -$3.40M.
| Period end | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 3 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 6 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 9 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2024-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$1.07M derived: sum of 2 quarters · filed 2024-11-14 | -$3.32M 10-Q · filed 2024-11-14 | -$3.04M derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | -$2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$4.33M 10-Q · filed 2024-08-14 | -$4.05M derived: sum of 3 quarters · filed 2024-08-14 | -$1.29M derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-03-31 | -$2.25M 10-Q · filed 2024-05-15 | -$1.97M derived: sum of 2 quarters · filed 2024-05-15 | $785.00K derived: sum of 3 quarters · filed 2024-11-14 | $4.96M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-12-31 | $278.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $3.04M derived: sum of 2 quarters · filed 2024-11-14 | $7.21M derived: sum of 3 quarters · filed 2024-11-14 | $6.42M 10-K · filed 2024-03-15 |
| 2023-09-30 | $2.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $6.93M derived: sum of 2 quarters · filed 2024-11-14 | $6.14M 10-Q · filed 2024-11-14 | $3.53M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $4.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $3.38M 10-Q · filed 2024-08-14 | $773.00K derived: sum of 3 quarters · filed 2024-08-14 | $3.01M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$792.00K 10-Q · filed 2024-05-15 | -$3.40M derived: sum of 2 quarters · filed 2024-05-15 | -$1.16M derived: sum of 3 quarters · filed 2024-05-15 | $486.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$368.00K derived: sum of 2 quarters · filed 2024-03-15 | $1.28M derived: sum of 3 quarters · filed 2024-03-15 | $912.00K 10-K · filed 2024-03-15 |
| 2022-09-30 | $2.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.88M derived: sum of 2 quarters · filed 2023-11-09 | $3.52M 10-Q · filed 2023-11-09 | $2.44M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $1.28M 10-Q · filed 2023-08-11 | $199.00K derived: sum of 3 quarters · filed 2023-10-03 | $1.21M derived: sum of 4 quarters · filed 2023-10-03 |
| 2022-03-31 | -$366.00K 10-Q · filed 2023-05-12 | -$1.45M derived: sum of 2 quarters · filed 2023-10-03 | -$440.00K derived: sum of 3 quarters · filed 2023-10-03 | -$217.00K derived: sum of 4 quarters · filed 2023-10-03 |
| 2021-12-31 | -$1.08M derived: 8-K 12 month − 10-Q 9 month · filed 2023-10-03 | -$74.00K derived: sum of 2 quarters · filed 2023-10-03 | $149.00K derived: sum of 3 quarters · filed 2023-10-03 | -$773.00K 8-K · filed 2023-10-03 |
| 2021-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.23M derived: sum of 2 quarters · filed 2022-11-14 | $308.00K 10-Q · filed 2022-11-14 | $3.45M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $223.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$699.00K 10-Q · filed 2022-08-12 | $2.44M derived: sum of 3 quarters · filed 2022-08-12 | |
| 2021-03-31 | -$922.00K 10-Q · filed 2022-05-13 | $2.22M derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-11 | -$3.40M 10-K · filed 2022-04-11 | ||
| 2020-09-30 | -$6.55M 10-Q · filed 2021-11-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |